Hugel, Inc. (KOSDAQ:145020)
South Korea
· Delayed Price · Currency is KRW 223,000
+2,000 (0.90%)
At close: Dec 5, 2025
Hugel Revenue
Hugel had revenue of 105.90B KRW in the quarter ending September 30, 2025, with 0.75% growth. This brings the company's revenue in the last twelve months to 404.19B, up 11.11% year-over-year. In the year 2024, Hugel had annual revenue of 373.05B with 16.69% growth.
Revenue (ttm)
404.19B
Revenue Growth
+11.11%
P/S Ratio
5.96
Revenue / Employee
680.45M
Employees
589
Market Cap
2,408.69B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 373.05B | 53.35B | 16.69% |
| Dec 31, 2023 | 319.70B | 38.02B | 13.50% |
| Dec 31, 2022 | 281.68B | 49.82B | 21.49% |
| Dec 31, 2021 | 231.86B | 20.82B | 9.87% |
| Dec 31, 2020 | 211.04B | 6.47B | 3.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,504.84B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| ABL Bio | 88.44B |
| SK Biopharmaceuticals | 675.41B |
| Yuhan | 2,136.67B |
| LigaChem Biosciences | 159.27B |
| Peptron | 6.19B |